SCHEMBL6767671

SCHEMBL6767671

CCCCCCCOc1ccc(C(=O)Nc2ccc(S(=O)(=O)CC(C)(O)C(=O)NO)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.52
TP53 P04637 1/20 0.52
NPC1 O15118 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
LMNA P02545 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
STAT3 P40763 1/20 0.50
S1PR1 P21453 3/20 0.48
S1PR3 Q99500 3/20 0.48
NR1H4 Q96RI1 2/20 0.48
KDM4E B2RXH2 1/20 0.48
PPARG P37231 1/20 0.48
S1PR4 O95977 1/20 0.47
S1PR5 Q9H228 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
MMP1 P03956 1/20 0.47
MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6767959 0.97 MAPT (0.55) MAPTTP53NPC1RXFP1LMNA
SCHEMBL6768715 0.84 KDM4E (0.57) MAPTTP53NPC1SMN1; SMN2NR1H4
SCHEMBL6764678 0.82 ENPP1 (0.53) NPC1LMNANR1H4KDM4ECA1
SCHEMBL6764639 0.80 PRMT1 (0.55) MAPTLMNASMN1; SMN2KDM4ECA12
SCHEMBL6773991 0.76 RAB9A (0.54) MAPTLMNASMN1; SMN2MEN1KMT2A
SCHEMBL22192246 0.76 SMN1; SMN2 (0.81) MAPTTP53NPC1LMNASMN1; SMN2
SCHEMBL6768589 0.76 AR (0.46) MAPT
SCHEMBL6764878 0.75 TP53 (0.56) MAPTTP53NPC1LMNASMN1; SMN2
SCHEMBL8363016 0.75 SMN1; SMN2 (0.67) MAPTTP53NPC1LMNASMN1; SMN2
SCHEMBL2832501 0.75 SMN1; SMN2 (0.67) MAPTTP53NPC1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6716844-B2 ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS PHARMACIA CORPORATION 2004-04-06 US disclosed
EP-0984959-B1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS PHARMACIA CORP (US) 2003-09-24 EP disclosed
US-20020173508-A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds PHARMACIA CORPORATION 2002-11-21 US disclosed
US-6362183-B1 PROTEASE INHIBITORS; RHEUMATIC DISEASES; ANTITUMOR AGENTS G. D. SEARLE & COMPANY 2002-03-26 US disclosed
EP-0984959-A4 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO CO (US) 2001-05-02 EP disclosed
EP-0984959-A1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 2000-03-15 EP disclosed
WO-1998039326-A1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 1998-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173508-A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds MMP1, MMP2, MMP3 MAPT 4266/4885TP53 1109/4885NPC1 2284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.